$1.34
-0.13-8.5%
Last update: Nov 4, 7:10 AM
CalciMedica Inc (CALC) Stock Price, Quote, News & History
CALCNASDAQ
FDA raises no objections to CalciMedica revised Phase 2 KOURAGE trial, allowing Auxora dosing to resume for acute kidney injury.
You can purchase shares of CalciMedica (NASDAQ:CALC) through any online brokerage.
Other companies in CalciMedica’s space includes: Eli Lilly and Co (NYSE:LLY), Johnson & Johnson (NYSE:JNJ), Merck & Co Inc (NYSE:MRK), Novartis AG (NYSE:NVS) and AstraZeneca PLC (NYSE:AZN).
CalciMedica has a consensus price target of $74.00.
The stock price for CalciMedica (NASDAQ: CALC) is $1.5 last updated November 4, 2026 at 7:10 AM EST.
There are no upcoming dividends for CalciMedica.
CalciMedica does not have any upcoming earnings scheduled.
There is no upcoming split for CalciMedica.
CalciMedica is in the Health Care sector and Pharmaceuticals industry. They are listed on the NASDAQ.
CalciMedica Inc is a clinical-stage biopharmaceutical company focused on developing therapeutics that treat serious illnesses driven by inflammatory and immunologic processes and direct cellular damage. Its product candidates act upon calcium...
